Jefferies Raises Price Target on WAVE Life Sciences (WVE) From $28 to $42
FREE Breaking News Alerts from StreetInsider.com!
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Leerink Partners Assumes WAVE Life Sciences (WVE) at Outperform
November 10, 2016 6:56 AM ESTLeerink Partners assumes coverage on WAVE Life Sciences (NASDAQ: WVE) with a Outperform rating and a price target of $45.00.
Analyst Paul Matteis commented, "In the context of recent safety setbacks for leading players in the oligonucleotide based therapeutic (OBT) space, we believe WVE's proprietary... More
